

Supplementary Material

Cost Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England and Wales

Diana Weidlich¹; Laurent Servais^{2,3}; Imran Kausar⁴; Ruth Howells⁵; Matthias Bischof⁶

¹Health Economics, Clarivate, Frankfurt am Main, Germany; ²MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK; ³Neuromuscular Center of Liège, Department of Paediatrics, Hospital and University of Liège, Liège, Belgium; ⁴Novartis Gene Therapies, London, UK; ⁵Health Technology Assessment, Clarivate, Manchester, UK; ⁶Novartis Gene Therapies GmbH, Rotkreuz, Switzerland

Corresponding Author:

Diana Weidlich, MSc

Clarivate

Mayfarthstrasse 11

Frankfurt am Main 60314

Germany

E-mail: Diana.Weidlich@Clarivate.com

A. Cost inputs for running scenario analysis: societal perspective

Table S1. Societal costs: cost summary per health state

Costs (£)	Health state E	Health state D	Health state C	Health state B	Health state A
Annual indirect costs	22,999	22,999	16,560	0	0
Annual carer costs	48,004	48,004	30,243	0	0
Onasemnogene abeparvovec /Risdiplam - transport costs for treatment	21	16	10	5	5
Nusinersen - transport costs for treatment (plus dosing related visits calculated below)	21	16	16	16	16
BSC - transport costs for treatment	31	31	31	0	0

BSC best supportive care.

Table S2. Societal costs: indirect cost inputs

Indirect costs	Input value
Average labor force participation rate (%) [1]	75
Average working hours per year [2]	1,934
Percentage of work hours lost per health state	
Health state E [3]	100
Health state D [3]	100
Health state C [3]	72
Health state B ^a	0
Health state A ^a	0
Average hourly wage (£) [2]	16
Productivity cost per hour (£) [4]	34
Start working age (years) ^a	18 ^a
End working age (years) [5]	68

^aBased on assumption.

Table S3. Societal costs: caregiver cost inputs

Caregiver costs	Input value
Average hourly wage for a caregiver (£) [6]	33
Percentage of patients requiring a carer per health state ^a	
Health state E	100
Health state D	100
Health state C	63
Health state B	0
Health state A	0

^aBased on assumption.

Table S4. Societal costs: transport cost inputs

	Input value
Percentage of patients that incur transport costs ^a	100
Average distance to academic hospital (kilometer) [7]	9.0
Cost per kilometer (£)	0.3
Parking per visit (£) [8]	0.0
Cost per kilometer taxi (£) [9]	4.9
Total transport costs per visit (£) [10]	5.2

^aBased on assumption.

Table S5. Societal costs: average number of hospital visits per year

	Average number of visits (per year) onasemnogene abeparvovec /risdiplam^{a,b}	Average number of visits (per year) nusinersen (plus dosing visits)^{a,b}	Average number of visits (per year) BSC^a
Health state E	4	4	6
Health state D	3	3	6
Health state C	2	3	6
Health state B	1	3	0
Health state A	1	3	0

BSC best supportive care.

^aBased on assumption.

^bBased expert opinion.

B. Results


B.1. Proportion of SMA patients, alive and by level of motor milestone achievement over time

To provide additional insight on the main drivers of health gains and health care cost savings associated with NBS and early treatment, the percentage of patients residing in each of the six health states of the model was computed at different time points to follow the children's development over time. The results of this analysis under NBS and no NBS from 5 years to 30 years of follow-up are provided in **Figs. S1** and **S2** below.

The main key findings of the analysis are the following:


- With NBS and early treatment, from the age of 5 years old onwards, approximately 80% of children with SMA will sit and walk independently, as opposed to approximately 20% of children with no NBS who are clinically diagnosed.
- In the current treatment situation with no NBS in place, for most patients with SMA, sitting will be the highest motor milestone that they will ever achieve.
- Without NBS and early treatment, less than 50% of children with SMA are expected to live beyond the age of 30, compared with 80% of patients with NBS and early treatment. In fact, with NBS and early treatment, 70% of patients are expected to reach the age of 70 versus less than 20% of patients diagnosed symptomatically.

Figure S1. Percentage of SMA patients, alive and by motor milestone achievement over time, with NBS and early treatment



BRND broad range of normal development; *NBS* newborn screening; *PAV* permanent assisted ventilation.

Figure S2. Percentage of SMA patients, alive and by motor milestone achievement over time, in the current situation: no NBS and treatment at symptom onset



BRND broad range of normal development; *NBS* newborn screening; *PAV* permanent assisted ventilation.

Table S6. Percentage of SMA patients at age 70, alive and by motor milestone achievement over time, under NBS and early treatment compared with no NBS and treatment at symptom onset

	Dead	Non-sitter (PAV)	Non-sitter (no PAV)	Sitter	Walker	BRND	Sum
SMA patients identified via NBS and treated immediately upon diagnosis	33%	0%	0%	0%	0%	67%	100%
SMA patients treated at symptom onset	82%	0%	0%	2%	0%	16%	100%

BRND broad range of normal development; *NBS* newborn screening; *PAV* permanent assisted

ventilation; *SMA* spinal muscular atrophy.

B.2. Economic outcomes per SMA patient

Table S7. Undiscounted and discounted disaggregated costs and QALYs per SMA patient under NBS and no NBS

	Costs per SMA patient		
	NBS	No NBS	Increment
Disaggregated cost results — undiscounted			
Screening costs ^a	£46,200	£1,200	£45,000
Drug acquisition and administration costs	£4,668,496	£6,132,232	–£1,463,736
Medical care costs	£428,274	£1,396,914	–£968,640
Total undiscounted cost saving net of screening costs			–£2,387,376
Disaggregated cost results — discounted at 3.5% p.a.			
Screening costs ^a	£46,200	£1,200	£45,000
Drug acquisition and administration costs	£2,346,391	£2,949,844	–£603,452
Medical costs	£342,703	£847,000	–£504,297
Total discounted cost saving net of screening costs			–£1,062,749
	QALYs per SMA patient		
	NBS	No NBS	Increment
Total undiscounted QALY gain	56	24	32
Total QALY gain discounted at 3.5% p.a.	19	10	9

NBS newborn screening; *p.a* per annum; *QALY* quality-adjusted life year; *SMA* spinal muscular atrophy.

^aScreening costs include £4.54 for the heel-prick test and £1,200 for the confirmatory genetic test. A total of 58.8 SMA patients receive the confirmatory genetic test under both NBS and no NBS. Under NBS, 585,195 newborns receive the heel-prick test.

Newborn screening and early treatment are expected to provide infants at risk for SMA an additional 32 (undiscounted) years at full health when compared with the current situation in which patients with SMA are treated at symptom onset.

Implementing NBS and providing early treatment are also expected to generate an overall discounted cost savings, net of the cost of screening all newborns, of more than £1 million per SMA patient. These savings capture savings in medical care costs, such as care during hospital admissions, breathing equipment, and other costly health care services, and a reduction in drug acquisition costs because of different treatment patterns used for treating presymptomatic versus symptomatic patients (see **Table 1** in main document).

REFERENCES

1. Office for National Statistics. Labour market overview, UK: August 2019. 13 Aug 2019.
<https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/uklabourmarket/august2019>. Accessed 18 Jan 2023.
2. Office for National Statistics. Average actual weekly hours of work for full-time workers (seasonally adjusted). 2019.
<https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/timeseries/ybuy/lms/previous>. Accessed 18 Jan 2023.
3. Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. *Orphanet J Rare Dis*. 2016;11(1):58.
4. Office for National Statistics. Regional labour productivity, including industry by region, UK: 2019. 2019.
<https://www.ons.gov.uk/economy/economicoutputandproductivity/productivitymeasures/bulletins/regionallabourproductivityincludingindustrybyregionuk/2019>. Accessed 18 Jan 2023.
5. Department for Work & Pensions. Policy paper. State pension age timetable. 15 May 2014.
<https://www.gov.uk/government/publications/state-pension-age-timetable/state-pension-age-timetable>. Accessed 18 Jan 2023.
6. Curtis L, Burns A. Unit Costs of Health and Social Care 2020. Personal Social Services Research Unit (PSSRU), University of Kent. DOI: 10.22024/UniKent/01.02.84818.
<https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/>. Accessed 18 Jan 2023.

7. The Health Foundation. QualityWatch: Focus on distance from home to emergency care. Feb 2014. <https://www.health.org.uk/publications/qualitywatch-focus-on-distance-from-home-to-emergency-care>. Accessed 18 Jan 2023.
8. Department of Health & Social Care. NHS car parking guidance 2021 for NHS Trusts and NHS Foundation Trusts. 2021. <https://www.gov.uk/government/publications/nhs-patient-visitor-and-staff-car-parking-principles/nhs-patient-visitor-and-staff-car-parking-principles>. Accessed 30 April 2022.
9. Transport for London. Taxi fares. 2 Jan 2020. <https://tfl.gov.uk/modes/taxis-and-minicabs/taxi-fares>. Accessed 18 Jan 2023.
10. NimbelFins. Average Cost to Run a Car UK. 2022. <https://www.nimblefins.co.uk/cheap-car-insurance/average-cost-run-car-uk>. Accessed 30 April 2022.